<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0A517281-5783-4455-80D8-CFDF92A33C19"><gtr:id>0A517281-5783-4455-80D8-CFDF92A33C19</gtr:id><gtr:firstName>Rodger</gtr:firstName><gtr:surname>Duffin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B9C3C494-3A9C-4866-8022-D79B29D2CD88"><gtr:id>B9C3C494-3A9C-4866-8022-D79B29D2CD88</gtr:id><gtr:firstName>Adriano</gtr:firstName><gtr:surname>Rossi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/670260BC-6C2F-4969-AC3A-605AC2879977"><gtr:id>670260BC-6C2F-4969-AC3A-605AC2879977</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Haslett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK013386%2F1"><gtr:id>E6548355-DC48-4761-842F-28C4F50438FA</gtr:id><gtr:title>The Role of Cyclin-Dependent Kinase-9 Inhibition in Promoting the Resolution of Chronic Inflammation</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K013386/1</gtr:grantReference><gtr:abstractText>Disordered inflammation is responsible for most of the diseases afflicting western society, including hardening of the arteries (causing heart attacks, stroke and peripheral vascular disease), lung diseases (including chronic bronchitis and asthma), crippling rheumatoid and osteoarthritis, and the commonest forms of liver and kidney disease necessitating transplantation. Despite the huge burden of illness, loss of work and ultimately death, there is yet no effective drug therapy for most of these conditions.
Previous approaches to drug development have been targeted at interfering at single points within a hugely complex process that involves thousands of mediators, many of which duplicate and triplicate each other's effects. With MRC support over the last twenty years we have been taking an entirely different approach. While some forms of inflammation (pneumonia and acute gout, for example) cause dramatic inflammatory diseases they have the capacity to resolve completely with no residual damage to surrounding tissues. Starting from this observation we have been studying how these conditions resolve in order to generate new therapies for the vast majority of inflammatory diseases that fail to resolve 'in the fashion nature intended' and therefore result in chronic inflammation and ill-health.
Our major early discovery was that certain damaging white blood cells need to undergo a form of 'silent suicide' and be quietly removed by local scavenger cells in order for inflammation to resolve effectively. We spent several years working out the detailed mechanisms of this process in order to attempt to harness them for therapeutic gain. In the 'test-tube' we found many ways of 'driving' these suicide and clearing-up processes, but whenever we tried to reproduce the results in mouse models of human disease the beneficial effects were counteracted by the presence of powerful cell-survival factors in live tissues. 
The 'breakthrough' came at the beginning of our current MRC programme grant when we showed that agents called cyclin-dependent kinase (CDK) inhibitor drugs not only drove the cell suicide process in the presence of survival factors in the test tube, but greatly accelerated the rate of resolution in mouse lung models of human inflammatory/scarring diseases. This effectively 'squared the circle' on twenty years of preparatory work. 
In the past four years we have homed in on the specific molecules involved in this exciting discovery in order to build a strong scientific foundation for better targeted, less toxic new drugs. We have now clearly identified the molecule CDK9 for close attention in our new research programme, and shown that CDK inhibitor drugs not only drive cell suicide but also cause the 'scavenger' cells to release anti-inflammatory agents, thus adding to the drug's potential therapeutic benefit. Furthermore, we have shown that CDK inhibitor drugs cause resolution of inflammation not only in the lung but also in a mouse model of the inflammatory process responsible for hardening of the arteries and its consequences. Thus in our new programme of research we will extend our studies to clinically relevant models of vascular, liver and kidney disease, in the likelihood that our work will have widespread relevance for the development of new treatments for inflammatory/scarring diseases of all organs.</gtr:abstractText><gtr:technicalSummary>By demonstrating that CDK inhibitor drugs (CDKi) promote the resolution of lung inflammation through a process which involves 'driving' neutrophil apoptosis, we achieved a key aim of many years of MRC-funded research - showing that resolution mechanisms could be harnessed for potential therapeutic benefit. While CDKi (e.g., R-roscovitine) are beginning to be trialled in humans for various cancers, it is recognised that their specificity and toxicity profiles are not yet ideal. 
We have now generated persuasive in vitro and in vivo preliminary data that CDK9 is the key target of the CDKi in a process that involves down-regulation of Mcl-1. The importance of CDK9 in vivo is supported by pilot data using transgenic zebrafish treated with morpholino antisense oligimers to specifically knockdown CDK9. We have also discovered that CDKi inhibit release of pro-inflammatory mediators from stimulated macrophages (without inhibiting efferocytosis) in what is likely to represent an additional pro-resolution benefit. We have recently shown identical pro-resolution effects of CDKi in eosinophilic inflammation, in bleomycin-induced fibrosis and, excitingly, in a mouse model of atherogenesis.
In the proposed programme we will interrogate the hypothesis that CDK9 is pivotal in maintaining chronic inflammation and their inhibition induces the resolution of chronic inflammatory/scarring diseases of the lungs and other organs. Specifically we will:

1. Test our hypothesis in zebrafish, employing a novel model of chronic atheromatous inflammation and using specific molecular knockdown approaches in
 genetically modified fish.
2. Confirm the pivotal status of CDK9 in models of chronic inflammation in mice, prioritising the use of a myeloid-specific inducible CDK9 knockout mouse.
3. Establish proof-of-concept assays of pro-resolution effects of CDK9 inhibition in human inflammatory macrophages to provide a platform for drug discovery.</gtr:technicalSummary><gtr:potentialImpactText>The worldwide healthcare burden of inflammatory/scarring diseases of the lung and other organs is undeniable, as is the fact that most of these are therapeutically intractable and ultimately fatal. Our MRC-supported research showing that the processes by which inflammation resolves 'naturally' can be harnessed in a new approach to treating these diseases has already generated considerable impact. Indeed our twenty-year 'discovery pathway' is often used as an example of the cellular&amp;gt;animal model&amp;gt;human disease translation paradigm.
Our work has already resulted in considerable academic and commercial impact. It has attracted large numbers of high-quality clinical and non-clinical training fellows and continues to do so. Our proposed research programme is positioned directly at the translational interface, in terms of both clinical and commercial exploitation:
1. Our work on CDK inhibitor drugs in lung inflammation (Nature Medicine, 2006 which has been cited at least 164 times) has paved the way for a new therapeutic approach to treating inflammatory disease. We have already filed a patent application entitled 'Use of CDK inhibitor for the treatment of granulocyte mediated disorders' (No 0325931), but our proposed research on CDK9 will lead to better targeted drugs with better toxicity profiles. These will also be patented and commercially exploited.
2. The extension of our findings into a platform of potential new treatments for atheromatous vascular disease, liver and kidney fibrosis will add enormously to the impact of our current and proposed research in chronic inflammatory lung disease.
3. The research of our group has generated considerable academic impact in the inflammation and apoptosis fields, and has influenced the research of numerous groups worldwide. Our publications are widely read and highly cited. Our original observation of neutrophil apoptosis (J Clin Invest, 1989) has been cited more than 1100 times and has stimulated new research by academic groups worldwide. Since 1989 a total of &amp;gt;9583 academic papers have been published on 'neutrophil', 'eosinophil' or 'granulocyte' apoptosis, or programmed cell death, and most of Haslett's (&amp;gt;18,239) citations relate to granulocyte apoptosis. The metric for the applicants are as follows: AG Rossi (H-factor-36, total citations &amp;gt;4542) and C Haslett (H-factor-65; total citations &amp;gt;18,224. R. Duffin, the named senior scientist, has an H-factor of 24 with total citations of &amp;gt;2,933). It is predicted that these metrics will continue to grow proportionately as new publications derive from our proposed work.
4. The group continues to enjoy an excellent record of attracting high-quality scientific trainees from home and abroad and for guiding them on successful career paths. Haslett has been responsible for the supervision/sponsorship of more that twenty-five (MRC and WT) clinical training fellows at different levels of seniority, many of whom now run their own research groups in branches of this field. Two new Training Fellows are now associated with the current programme. The UoE CMVM has a strong history of appointing Programme Grant senior scientists to permanent positions at the end of the grant period. Previous examples include Professors Ian Dransfield and Adriano Rossi (who now heads the 'Inflammation Resolution' programme in the CIR). If the current proposal is awarded, CMVM is committed to the same plan for Dr Rodger Duffin. Thus the research programme will continue to have an important impact on scientific training and career development. 
 
Our Research proposal therefore addresses a major area of unmet human need and fits with a number of strategic objectives in the MRC five-year Strategic Plan (2009-2014):-
- Improve human health
- Promote translation of basic research discoveries into new/improved healthcare
- Encourage commercial exploitation, for the benefit of the UK's health and economy
- Attract and train first-rate researchers.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-10-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2012021</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr Chengcan Yao</gtr:description><gtr:id>AD221F1E-C04B-4BBE-9295-700261057A93</gtr:id><gtr:impact>Joint applications to research grant awarding bodies (MRC, Wellcome Trust) are in progress. 

Several manuscripts have are in progress two of which have been submitted for publication and one has already been published (please see below). 

Duffin R, O'Connor RA, Crittenden S, Forster T, Yu C, Zheng X, Smyth D, RobbCT, Rossi F, Skouras C, Tang S, Richards J, Pellicoro A, Weller RB, Breyer RM,Mole DJ, Iredale JP, Anderton SM, Narumiya S, Maizels RM, Ghazal P, Howie SE,Rossi AG, Yao C. Prostaglandin E2 constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. Science. 2016 Mar 18;351(6279):1333-8. dos: 10.1126/science.aad9903. PubMed PMID: 26989254; PubMed Central PMCID: PMC4841390.</gtr:impact><gtr:outcomeId>58c9883f805b47.26206859-1</gtr:outcomeId><gtr:partnerContribution>Dr Chengcan Yao has brought expertise on important immune cells, the innate lymphoid cells, that has led to a novel avenue of research for my research team.</gtr:partnerContribution><gtr:piContribution>Dr Chengcan Yao is a young independent researcher who has recently joined the MRC Centre for Inflammation Research. Members of my team (Dr Rodger Duffin, Calum Robb and Jennifer Felton) have a highly successful working collaboration with him and his group.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Foz do Iguazu, Brazil. &quot;Pharmacological strategies to enhance the resolution of inflammation&quot; 48th Brazilian Congress of Pharmacology and Experimental Therapeutics and the 21st Latin American Congress of Pharmacology (47th October 2016). Talk on the 6th October 2016.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7CDB5AB2-56E2-49A3-9DA6-695D7DF0931E</gtr:id><gtr:impact>Foz do Iguazu, Brazil. &amp;quot;Pharmacological strategies to enhance the resolution of inflammation&amp;quot; 48th Brazilian Congress of Pharmacology and Experimental Therapeutics and the 21st Latin American Congress of Pharmacology (47th October 2016). Talk on the 6th October 2016.</gtr:impact><gtr:outcomeId>58c5a34ddc5267.17730254</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.socesfar.es/index.php/our-services-4/our-services-5/our-services-9/250-48-brazilian-congress</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>55th International Conference on the Bioscience of Lipids. Aberdeen, Scotland.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D15C2AC8-ECF8-4D8D-BFC1-41CCC264529F</gtr:id><gtr:impact>55th International Conference on the Bioscience of Lipids. Aberdeen, Scotland. June 23-27th 2014. Invited speaker- plenary session.</gtr:impact><gtr:outcomeId>58c59d5273b650.62391870</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://conference.researchbib.com/view/event/36404</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Edinburgh. Edinburgh Infectious Disease Conference &quot;Resolution of Inflammation: Implications for Infectious Diseases&quot; 20th May 2015.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D3B7A793-F878-42A7-A0B5-D38E4A838B2A</gtr:id><gtr:impact>University of Edinburgh. Edinburgh Infectious Disease Conference &amp;quot;Resolution of Inflammation: Implications for Infectious Diseases&amp;quot; 20th May 2015.</gtr:impact><gtr:outcomeId>58c5a09ece06d0.39826299</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1.	British Society for Immunology Inflammation Affinity Group, in conjunction with the Manchester Immunology Group. Manchester at the &quot;Inflammation and Disease&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>38349122-629F-464E-9167-FC2DFE4B73E7</gtr:id><gtr:impact>British Society for Immunology Inflammation Affinity Group, in conjunction with the Manchester Immunology Group. Manchester at the &amp;quot;Inflammation and Disease&amp;quot; conference on 9th -10th of September, 2014.</gtr:impact><gtr:outcomeId>58c59e7f765147.70467340</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pharmacology, Toxicology and Therapeutics Seminar, University of Edinburgh</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E7ED2DA1-B02E-429A-997B-623ED926F64F</gtr:id><gtr:impact>Pharmacology, Toxicology and Therapeutics Seminar, &amp;quot;Killing inflammatory cells to resolve inflammation&amp;quot; Monday 5th November 2012, University of Edinburgh, QMRI.</gtr:impact><gtr:outcomeId>58c5988e5a9920.34692489</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Heriot-Watt University, School of Life Science, Edinburgh, UK. &quot;Strategies for enhancing the resolution of inflammation&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DB0B01C9-969B-40F2-B1EC-31760CA3FCA9</gtr:id><gtr:impact>Heriot-Watt University, School of Life Science, Edinburgh, UK. &amp;quot;Strategies for enhancing the resolution of inflammation&amp;quot; 25th November, 2015</gtr:impact><gtr:outcomeId>58c5a1bb9bdf14.20187173</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Milan, Resolution of Inflammation in Pulmonary Diseases , 24th March 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>445F8F68-679B-4696-AD8A-1CAEC5CE6CF6</gtr:id><gtr:impact>University of Milan, Resolution of Inflammation in Pulmonary Diseases , 24th March 2015</gtr:impact><gtr:outcomeId>58c59f9216c3f7.99578709</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCB, Slough, UK. &quot;Targeting neutrophil apoptosis to resolve lung inflammation&quot; 3rd November 2016.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E24EB2BA-8C5F-4431-8414-83E7F57D3D9E</gtr:id><gtr:impact>UCB, Slough, UK. &amp;quot;Targeting neutrophil apoptosis to resolve lung inflammation&amp;quot; 3rd November 2016.</gtr:impact><gtr:outcomeId>58c5a397df6277.29405701</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Banff, Canada 2017. &quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&quot;. 10th Biennial Banff Inflammation Workshop (26-29th January 2017). Talk on 27th January 2017.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>60D5DF34-3036-45D5-8518-8EC8CF46FB34</gtr:id><gtr:impact>Banff, Canada 2017. &amp;quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&amp;quot;. 10th Biennial Banff Inflammation Workshop (26-29th January 2017). Talk on 27th January 2017.</gtr:impact><gtr:outcomeId>58c5a4176cb082.14760479</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.ucalgary.ca/biw2017/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Our papers are frequently highlighted in the press</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ED7195DB-A0A6-46E2-B284-D802AF2ECAA9</gtr:id><gtr:impact>A list of manuscript published by my research team and collaborators that have been highlighted in the University websites and twitter accounts and the general press are listed below (some examples of media outlets have been given). 

Dorward DA, Felton JM, Robb CT, Craven T, Kipari T, Walsh TS, Haslett C, Kefala K, Rossi AG, Lucas CD. The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome. Thorax. 2017 Feb;72(2):182-185. doi: 10.1136/thoraxjnl-2016-209229. PubMed PMID: 27965411; PubMed Central PMCID: PMC5284332.

http://science.newsln.jp/news/2016110315440074.html
https://scifeeds.com/news/immune-cell-insight-offers-hope-for-tackling-deadly-lung-condition/

Hoodless LJ, Lucas CD, Duffin R, Denvir MA, Haslett C, Tucker CS, Rossi AG. Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo. Sci Rep. 2016 Nov 11;5:36980. dei: 10.1038/srep36980. PubMed PMID: 27833165; PubMed Central PMCID: PMC5105078.

http://www.eveningtimes.co.uk/news/14987467.Zebrafish_used_by_Scots_scientists_to_help_study_new_therapies_for_lung_disorders/
http://www.heraldscotland.com/news/14987467.Zebrafish_used_by_Scots_scientists_to_help_study_new_therapies_for_lung_disorders/
http://scientists.trendolizer.com/2017/01/zebrafish-used-by-scots-scientists-to-help-study-new-therapies-for-lung-disorders.html


Brook M, Tomlinson GH, Miles K, Smith RW, Rossi AG, Hiemstra PS, van 't Wout EF, Dean JL, Gray NK, Lu W, Gray M. Neutrophil-derived alpha defensives control inflammation by inhibiting macrophage mRNA translation. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4350-5. dei: 10.1073/pnas.1601831113. PubMed PMID: 27044108; PubMed Central PMCID: PMC4843457.

http://immunitytales.com/a-molecular-brake-for-macrophage-driven-inflammation/
https://scifeeds.com/journal-article/neutrophil-derived-alpha-defensins-control-inflammation-by-inhibiting-macrophage-mrna-translation/
https://www.sciencedaily.com/releases/2016/04/160418120337.htm

Duffin R, O'Connor RA, Crittenden S, Forster T, Yu C, Zheng X, Smyth D, Robb CT, Rossi F, Skouras C, Tang S, Richards J, Pellicoro A, Weller RB, Breyer RM, Mole DJ, Iredale JP, Anderton SM, Narumiya S, Maizels RM, Ghazal P, Howie SE, Rossi AG, Yao C. Prostaglandin E2 constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. Science. 2016 Mar 18;351(6279):1333-8. dos: 10.1126/science.aad9903. PubMed PMID: 26989254; PubMed Central PMCID: PMC4841390

https://www.eurekalert.org/pub_releases/2016-03/uoe-iss031616.php
https://www.sciencedaily.com/releases/2016/03/160317150759.htm

Marwick JA, Dorward DA, Lucas CD, Jones KO, Sheldrake TA, Fox S, Ward C, Murray J, Brittan M, Hirani N, Duffin R, Dransfield I, Haslett C, Rossi AG. Oxygen levels determine the ability of glucocorticoids to influence neutrophil survival in inflammatory environments. J Leukoc Biol. 2013 Dec;94(6):1285-92. doi: 10.1189/jlb.0912462. PubMed PMID: 23964116; PubMed Central PMCID: PMC3855024.

https://bionews-tx.com/news/2014/03/12/chronic-bronchitis-emphysema-lung-disease-drug-ineffectiveness-explained-in-new-study/
https://stv.tv/news/east-central/266592-new-treatment-for-lung-diseases-a-step-closer-after-breakthrough/
https://m.medicalxpress.com/news/2013-12-oxygen-decrease-effectiveness-anti-inflammatory-therapies.html

Wheatley PS, Butler AR, Crane MS, Fox S, Xiao B, Rossi AG, Megson IL, Morris RE. NO-releasing zeolites and their antithrombotic properties. J Am Chem Soc. 2006 Jan 18;128(2):502-9. PubMed PMID: 16402837.

https://www.newscientist.com/article/mg18524856-700-pollution-fighter-turns-clot-buster/

Fox S, Wilkinson TS, Wheatley PS, Xiao B, Morris RE, Sutherland A, Simpson AJ, Barlow PG, Butler AR, Megson IL, Rossi AG. NO-loaded Zn(2+)-exchanged zeolite materials: a potential bifunctional anti-bacterial strategy. Acta Biomater. 2010 Apr;6(4):1515-21. toi: 10.1016/j.actbio.2009.10.038. PubMed PMID: 19861185.

http://www.ed.ac.uk/news/all-news/superbugs-231109


Duffin R, Leitch AE, Sheldrake TA, Hallett JM, Meyer C, Fox S, Alessandri AL, Martin MC, Brady HJ, Teixeira MM, Dransfield I, Haslett C, Rossi AG. The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1. FEBS Lett. 2009 Aug 6;583(15):2540-6. dos: 10.1016/j.febslet.2009.07.017. PubMed PMID: 19616548.

http://news.bbc.co.uk/1/hi/scotland/edinburgh_and_east/8403307.stm
https://www.sciencedaily.com/releases/2009/12/091209113846.htm
http://www.nursinginpractice.com/article/cancer-drug-may-work-asthma

Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, Gray M, Crescenzi E, Martin MC, Brady HJ, Savill JS, Dransfield I, Haslett C. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med. 2006 Sep;12(9):1056-64.

https://www.sciencedaily.com/releases/2006/09/060903150749.htm
https://www.eurekalert.org/pub_releases/2006-09/uoe-kso090106.php</gtr:impact><gtr:outcomeId>58c989a1dd4a17.14416649</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2009,2010,2013,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IUPHAR, Edinburgh, 2016. &quot;Pharmacological strategies to enhance the resolution of inflammation. NC-IUPHAR and BPS Focused Meeting on the Guide to Immunopharmacology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>567D7FA6-0CA5-4E7A-88E8-E98BB0C8ADDD</gtr:id><gtr:impact>IUPHAR, Edinburgh, 2016. &amp;quot;Pharmacological strategies to enhance the resolution of inflammation. NC-IUPHAR and BPS Focused Meeting on the Guide to Immunopharmacology (9-10th April, 2016). Talk on the 9th April 2016.</gtr:impact><gtr:outcomeId>58c5a219c100d2.22686390</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Convegno su Nuove Prospettive in Chimica Farmaceutica (NPCF7), Savigliano, Italy,  29-31 May 2013. Keynote Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9228B31D-0DAB-454E-81C5-3449EF51CB7D</gtr:id><gtr:impact>Convegno su Nuove Prospettive in Chimica Farmaceutica (NPCF7), Savigliano, Italy, 29-31 May 2013. Keynote Lecture &amp;quot;An introduction to the initiation, propagation and resolution of inflammation: Targeting the resolution of inflammation by pharmacological intervention&amp;quot; 20 May, 2013</gtr:impact><gtr:outcomeId>58c59a911b53a2.93269616</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cardiff University, Cardiff School of Dentistry. &quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&quot;. 3rd March 2017.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C1645A96-1BAE-4625-82D5-3F9F08F77BF1</gtr:id><gtr:impact>Cardiff University, Cardiff School of Dentistry. &amp;quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&amp;quot;. 3rd March 2017.</gtr:impact><gtr:outcomeId>58c5a474b6ebf8.54696341</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1.	Charles Darwin House, London, UK. Flow cytometric techniques for assessing apoptosis and efferocytosis of inflammatory cells. Advances in Cytometry 2015. The Terry Hoy Lecture,</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CC386FA0-71BF-450E-8A88-E30DAB39459E</gtr:id><gtr:impact>Charles Darwin House, London, UK. Flow cytometric techniques for assessing apoptosis and efferocytosis of inflammatory cells. Advances in Cytometry 2015. The Terry Hoy Lecture, 13th November 2015</gtr:impact><gtr:outcomeId>58c5a16e8f2c10.82900504</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1.	ESCCA 2016, Edinburgh, UK. &quot;Flow cytometric techniques for assessing apoptosis and efferocytosis of inflammatory cells: strategies for enhancing the resolution of inflammation. - A 'festival of cell analysis, apoptosis and inflammation' (11-14th September, 2016). Talk on the 14th September 2016.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5CE2C6B0-09D1-48AA-9F99-21E189939848</gtr:id><gtr:impact>ESCCA 2016, Edinburgh, UK. &amp;quot;Flow cytometric techniques for assessing apoptosis and efferocytosis of inflammatory cells: strategies for enhancing the resolution of inflammation. - A 'festival of cell analysis, apoptosis and inflammation' (11-14th September, 2016). Talk on the 14th September 2016.</gtr:impact><gtr:outcomeId>58c5a2b9ed74d1.01781705</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Sheffield, UK. Lecture in honour of Prof Moira Whyte</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>320FDA82-B128-4FD8-A881-70AAD73ACB1C</gtr:id><gtr:impact>University of Sheffield, UK. Lecture in honour of Prof Moira Whyte 'Modulation Of Inflammation Resolution &amp;amp; Apoptosis' June 25th 2014.</gtr:impact><gtr:outcomeId>58c59dbd302c89.93781703</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>R&amp;D Systems Symposium &quot;The Role of Cytokines and Signalling in Inflammation&quot;.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E04A1851-A3AD-4E79-A8FD-298372DBD4D6</gtr:id><gtr:impact>R&amp;amp;D Systems Symposium &amp;quot;The Role of Cytokines and Signalling in Inflammation&amp;quot;. Research Centre CAESAR, Ludwig-Erhard-Allee 2, 53175 Bonn. 15th October 2013.</gtr:impact><gtr:outcomeId>58c59bb57f4ac9.27519375</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1.	Edinburgh, SCRM. &quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&quot; Wellcome Trust Site Visit, 5th August, 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5368DCE3-A2B1-4E8D-9C77-B99C6F2EC10E</gtr:id><gtr:impact>Edinburgh, SCRM. &amp;quot;Therapeutic strategies to enhance the resolution of inflammation to promote tissue repair and regeneration&amp;quot; Wellcome Trust Site Visit, 5th August, 2016</gtr:impact><gtr:outcomeId>58c5a27762fbd0.73232820</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Edinburgh. QMRI, Public lecture &quot;Treating injured lungs by extinguishing inflammation&quot;. Feb 11th 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B54EF7E3-0573-46FB-8EED-3386076CE82B</gtr:id><gtr:impact>University of Edinburgh. QMRI, Public lecture &amp;quot;Treating injured lungs by extinguishing inflammation&amp;quot;. Feb 11th 2015</gtr:impact><gtr:outcomeId>58c59f2fd54a21.05722662</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>11th World Congress on Inflammation, Natal RN, Brazil, September, 21-25, 2013. Invited speaker &quot;Driving inflammatory cells apoptosis to resolve inflammation&quot;.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C604056-2A8E-46E7-912A-DAD955E1FAE2</gtr:id><gtr:impact>11th World Congress on Inflammation, Natal RN, Brazil, September, 21-25, 2013. Invited speaker &amp;quot;Driving inflammatory cells apoptosis to resolve inflammation&amp;quot;. Scheduled 24th Sept, 2013</gtr:impact><gtr:outcomeId>58c59b447da1d1.91312251</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature Reviews Immunology. Resolving Inflammation conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FA267ABE-F742-493F-BBB2-6AE12C824434</gtr:id><gtr:impact>Nature Reviews Immunology. Resolving Inflammation: Mechanisms and Drug Discovery, Keble College, Oxford, UK. April 1-3, 2012. Talk entitled &amp;quot;Targeting inflammatory cell apoptosis to resolve inflammation&amp;quot;. Invited speaker in plenary session.

URL- http://www.nature.com/content/conferences/23393-02.html?WT.i_dcsvid=%%LIST_ID%%-%%RECIPIENT_ID%%&amp;amp;WT.ec_id=MARKETING</gtr:impact><gtr:outcomeId>58c5977c8abdf3.45724082</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>16th ANCA and Vasculitis Meeting, Paris,</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3908435C-7E5C-4611-9A85-CC769009C53B</gtr:id><gtr:impact>16th ANCA and Vasculitis Meeting, Paris, 14-17th April 2013. Plenary lecture entitled &amp;quot;Apoptosis, apoptotic cell clearance and resolution of inflammation&amp;quot;</gtr:impact><gtr:outcomeId>58c59a0c92dda3.23282032</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.sciencedirect.com/science/journal/07554982/42/4</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>THE PETER E. DRESEL MEMORIAL LECTURE IN PHARMACOLOGY 31st March 2015, Halifax, Canada. March</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>827F115F-DA86-4B6B-94F3-B5A2A4B4280C</gtr:id><gtr:impact>THE PETER E. DRESEL MEMORIAL LECTURE IN PHARMACOLOGY 31st March 2015, Halifax, Canada. March. This was a prestigious yearly award in honour of Prof Dresel,</gtr:impact><gtr:outcomeId>58c5a02eac0265.04728135</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Goethe University, Translation Research Innovation- Pharma, Frankfurt. &quot;Resolution of Inflammation&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BB009560-790A-4F00-B1B2-762AB68B5AAD</gtr:id><gtr:impact>Goethe University, Translation Research Innovation- Pharma, Frankfurt. &amp;quot;Resolution of Inflammation&amp;quot; 6th July 2015</gtr:impact><gtr:outcomeId>58c5a10cb193f3.84590673</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Edinburgh, Edinburgh-Zhejiang Joint Symposium 2014. Resolving lung inflammation,</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7A1BCDE1-B5B8-4DBE-84FB-E13C1988BE4E</gtr:id><gtr:impact>University of Edinburgh, Edinburgh-Zhejiang Joint Symposium 2014. Resolving lung inflammation, 3rd Sept 2014</gtr:impact><gtr:outcomeId>58c59e1b9cf173.94106979</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Banff Inflammation Workshop, Banff, Canada.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C07E9181-D4F7-4736-A6B6-BA96F4944189</gtr:id><gtr:impact>The Banff Inflammation Workshop, Banff, Canada, (31 Jan - 3 Feb 2013). Invited speaker and plenary lecture '&amp;quot;Resolution solutions!&amp;quot;. 1st Feb 2013</gtr:impact><gtr:outcomeId>58c59953c65665.82949208</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.ucalgary.ca/irn/meeting/banff-inflammation-workshop-2013</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation &amp; Inflammation Disease Area, Basel, Switzerland.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8CC0400F-159B-4C4C-90DE-416FED98E1D3</gtr:id><gtr:impact>Novartis Institutes for BioMedical Research, Autoimmunity, Transplantation &amp;amp; Inflammation Disease Area, Basel, Switzerland. &amp;quot;Apoptosis, Efferocytosis and the Resolution of Inflammation&amp;quot;. 6th May 2014.</gtr:impact><gtr:outcomeId>58c59c762ed841.17477658</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Aberdeen, Scottish Society of Cytomics SCC 2014.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A55DE9F7-F308-44A6-9C36-AA4548D2F125</gtr:id><gtr:impact>University of Aberdeen, Scottish Society of Cytomics SCC 2014. &amp;quot;Flow cytometric techniques for isolating and analysing leucocytes&amp;quot; 25-26th Sept 2014.</gtr:impact><gtr:outcomeId>58c59ede2f9599.38559568</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A9A143F7-4D71-4916-BDAA-915C17299880</gtr:id><gtr:title>Induction of eosinophil apoptosis by hydrogen peroxide promotes the resolution of allergic inflammation.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71343debadb1a9cb68282d79c35a895a"><gtr:id>71343debadb1a9cb68282d79c35a895a</gtr:id><gtr:otherNames>Reis AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dff190868987.15931015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00CCC5C5-9A02-421E-BC28-8300718624F5</gtr:id><gtr:title>Key mechanisms governing resolution of lung inflammation.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab9ebc3e1cf3b8a546aa3b876c2d1c1"><gtr:id>4ab9ebc3e1cf3b8a546aa3b876c2d1c1</gtr:id><gtr:otherNames>Robb CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn><gtr:outcomeId>585d3295055e36.47989984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F90C2E5C-5CD8-4016-802A-DBDC985704D8</gtr:id><gtr:title>A randomized controlled trial of peripheral blood mononuclear cell depletion in experimental human lung inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc797cd3a172aa8fe324b25328d15fb5"><gtr:id>dc797cd3a172aa8fe324b25328d15fb5</gtr:id><gtr:otherNames>Barr LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_15352_22_23627345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D6D8219-C50A-4842-94AA-692F3FAB1E50</gtr:id><gtr:title>Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps.</gtr:title><gtr:parentPublicationTitle>Journal of inflammation (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92319dcc0dd9497cd4b579b4d0ce35fc"><gtr:id>92319dcc0dd9497cd4b579b4d0ce35fc</gtr:id><gtr:otherNames>Gray RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1476-9255</gtr:issn><gtr:outcomeId>pm_15352_22_23514610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16CFFC8E-98C5-43F0-9165-1F6D698FB4E4</gtr:id><gtr:title>Soluble tumour necrosis factor receptor-1 (sTNFR1) levels are positively associated with exercise intensity in athletes after strenuous off-road cycling.</gtr:title><gtr:parentPublicationTitle>The Journal of sports medicine and physical fitness</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37e0da7d90668c49da161e796d5336af"><gtr:id>37e0da7d90668c49da161e796d5336af</gtr:id><gtr:otherNames>Pussieldi GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-4707</gtr:issn><gtr:outcomeId>5437a060cf6450.47687909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF686F1E-D4B7-47FE-8CB5-DC5D20E51D18</gtr:id><gtr:title>Downregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lung.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5aeb0c67fdf9cb4756bd82fe23617d8f"><gtr:id>5aeb0c67fdf9cb4756bd82fe23617d8f</gtr:id><gtr:otherNames>Lucas CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>pm_540e14fe14f5c8987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D72EF89-66B2-4EF4-A3C2-97BB24C459F0</gtr:id><gtr:title>Decidual neutrophil infiltration is not required for preterm birth in a mouse model of infection-induced preterm labor.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e39684739d81aa8b533b15fd44bdf98"><gtr:id>3e39684739d81aa8b533b15fd44bdf98</gtr:id><gtr:otherNames>Rinaldi SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>54379f4a689f69.44131284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78DED89E-F4A3-4FD9-B7D9-D808B0E5367B</gtr:id><gtr:title>Eosinophils in the lung - modulating apoptosis and efferocytosis in airway inflammation.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00d1990086fa9920d761e77e429b9e24"><gtr:id>00d1990086fa9920d761e77e429b9e24</gtr:id><gtr:otherNames>Felton JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>543572c67f4d04.11993554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEDFDDD9-B3C5-4950-9902-06A5359F0EAF</gtr:id><gtr:title>Novel role for endogenous mitochondrial formylated peptide-driven formyl peptide receptor 1 signalling in acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5a748d133bf8d6.46523781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9E6F516-634C-4741-A078-5766BB2B9DE6</gtr:id><gtr:title>The &amp;quot;Phagocytic Synapse&amp;quot; and Clearance of Apoptotic Cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ceef0d0c17537733765e793fd49f911"><gtr:id>6ceef0d0c17537733765e793fd49f911</gtr:id><gtr:otherNames>Barth ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a2fda6914fc96.38066003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89471147-7D6E-4323-9CC3-ECDBBC291F45</gtr:id><gtr:title>Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34e9e205afb7e6ad8af86db4fddced53"><gtr:id>34e9e205afb7e6ad8af86db4fddced53</gtr:id><gtr:otherNames>Montanaro G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>pm_15352_22_23394865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3369E355-280E-4A5D-863A-48D98CF3033C</gtr:id><gtr:title>Prostaglandin E2 constrains systemic inflammation through an innate lymphoid cell-IL-22 axis.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3577fc614c979ce9faaaf0bb2f68e1e2"><gtr:id>3577fc614c979ce9faaaf0bb2f68e1e2</gtr:id><gtr:otherNames>Duffin R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5a324a0c5d4f44.03457433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EF064EC-703E-4161-8197-3CA3DAF1AD7F</gtr:id><gtr:title>Assays of eosinophil apoptosis and phagocytic uptake.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>543572463bf154.62741022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FAF36B0-0D05-483B-B9F5-E00FF4B16597</gtr:id><gtr:title>Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e37c74cabd9fe17a83cfb20d2bd4f3e5"><gtr:id>e37c74cabd9fe17a83cfb20d2bd4f3e5</gtr:id><gtr:otherNames>Hoodless LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>588b70d7cfd769.06972384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F67F7E0-5006-4F9F-8F80-45A04A6BEA93</gtr:id><gtr:title>The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>585d3b8cc0fa93.36009265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF7C646B-DC15-4EB4-B6D8-D2D6FFCCA263</gtr:id><gtr:title>The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>5675e11850690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45B97718-B1A4-4DFB-8063-D9FB067DC3CC</gtr:id><gtr:title>Resolution of inflammation: mechanisms and opportunity for drug development.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1abc409071bef4dd7a7a537e60551734"><gtr:id>1abc409071bef4dd7a7a537e60551734</gtr:id><gtr:otherNames>Alessandri AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>pm_15352_22_23583354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>417D3B27-C2F4-4C1F-B078-B2729D65ACDD</gtr:id><gtr:title>A novel assay of antimycobacterial activity and phagocytosis by human neutrophils.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fffeea0403dfb5c4fb207ad1992bd697"><gtr:id>fffeea0403dfb5c4fb207ad1992bd697</gtr:id><gtr:otherNames>Lowe DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>pm_15352_22_23332400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4F063A1-FEC9-45EF-BCD7-E4F67ED8246E</gtr:id><gtr:title>Leukoreduced blood transfusion does not increase circulating soluble markers of inflammation: a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea54da1f0ea914468d5cd720772836f"><gtr:id>2ea54da1f0ea914468d5cd720772836f</gtr:id><gtr:otherNames>Jiwaji Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>543570bc3d9e69.20913738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB9CE4B6-01B0-440A-8208-8477CB19CE2D</gtr:id><gtr:title>Emerging importance of omega-3 fatty acids in the innate immune response: molecular mechanisms and lipidomic strategies for their analysis.</gtr:title><gtr:parentPublicationTitle>Molecular nutrition &amp; food research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1330c5f0f6c22f28e7d109d8575fea43"><gtr:id>1330c5f0f6c22f28e7d109d8575fea43</gtr:id><gtr:otherNames>Maskrey BH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1613-4125</gtr:issn><gtr:outcomeId>pm_15352_22_23417926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9ADCED9-23FD-41E0-A05A-BB038E87F259</gtr:id><gtr:title>Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1838bc97f7415dab93171128fab5c33c"><gtr:id>1838bc97f7415dab93171128fab5c33c</gtr:id><gtr:otherNames>Mandal P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>54379e4c035689.52169618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54CC165C-8750-405F-856E-91C0DA21EF38</gtr:id><gtr:title>L13. Apoptosis, apoptotic cell clearance and resolution of inflammation.</gtr:title><gtr:parentPublicationTitle>Presse medicale (Paris, France : 1983)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86c64af2e3b978d2ca23d153357ec628"><gtr:id>86c64af2e3b978d2ca23d153357ec628</gtr:id><gtr:otherNames>Rossi AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0755-4982</gtr:issn><gtr:outcomeId>pm_15352_22_23474048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08B9BB96-F791-448F-9DF3-598212CBEDDF</gtr:id><gtr:title>Crosstalk between monocytes and myometrial smooth muscle in culture generates synergistic pro-inflammatory cytokine production and enhances myocyte contraction, with effects opposed by progesterone.</gtr:title><gtr:parentPublicationTitle>Molecular human reproduction</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c053b34d9521800e3fe7c369997bd68"><gtr:id>1c053b34d9521800e3fe7c369997bd68</gtr:id><gtr:otherNames>Rajagopal SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1360-9947</gtr:issn><gtr:outcomeId>5675e50ecbe89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93ECE924-D788-49D5-B951-176DAC63353F</gtr:id><gtr:title>Optical projection tomography permits efficient assessment of infarct volume in the murine heart postmyocardial infarction.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Heart and circulatory physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f76706732cc4158a7609b4aa9382a37e"><gtr:id>f76706732cc4158a7609b4aa9382a37e</gtr:id><gtr:otherNames>Zhao X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0363-6135</gtr:issn><gtr:outcomeId>56dff0f630d253.11856235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DD4B551-72F7-42EF-AC35-4A8D363EAB5B</gtr:id><gtr:title>Apoptotic cell clearance: basic biology and therapeutic potential.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fa755f6ae7ff2f224a6fefe2f3e7db8"><gtr:id>4fa755f6ae7ff2f224a6fefe2f3e7db8</gtr:id><gtr:otherNames>Poon IK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>doi_55f944944ae5506f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73410AB4-9A0F-4850-88A0-D75A6C2A6719</gtr:id><gtr:title>11?-Hydroxysteroid Dehydrogenase Type 1 Is Expressed in Neutrophils and Restrains an Inflammatory Response in Male Mice.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9821420b13976ee2721c4f260b8720d"><gtr:id>b9821420b13976ee2721c4f260b8720d</gtr:id><gtr:otherNames>Coutinho AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>585d663e8c55c9.20816633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A05F704-EC6C-410A-A629-2C4167B9AB22</gtr:id><gtr:title>The role of neutrophils in inflammation resolution.</gtr:title><gtr:parentPublicationTitle>Seminars in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e1367412532607fddf8649a4889ceaf"><gtr:id>9e1367412532607fddf8649a4889ceaf</gtr:id><gtr:otherNames>Jones HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1044-5323</gtr:issn><gtr:outcomeId>585d705c156fc5.26637840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21469FA1-C025-41B6-BFB4-1FD908D745CD</gtr:id><gtr:title>Models for the Study of the Cross Talk Between Inflammation and Cell Cycle.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e37c74cabd9fe17a83cfb20d2bd4f3e5"><gtr:id>e37c74cabd9fe17a83cfb20d2bd4f3e5</gtr:id><gtr:otherNames>Hoodless LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56dff0f66371d7.09849318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3470F75-72BB-4803-9C00-1DD083A253B0</gtr:id><gtr:title>Technical advance: autofluorescence-based sorting: rapid and nonperturbing isolation of ultrapure neutrophils to determine cytokine production.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>pm_14466_26_23667167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E749D205-D9EB-4AA7-A176-123F882B9800</gtr:id><gtr:title>Functional characterisation of human pulmonary monocyte-like cells in lipopolysaccharide-mediated acute lung inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of inflammation (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2829c4cc11fbdc037ce0c865e466528"><gtr:id>a2829c4cc11fbdc037ce0c865e466528</gtr:id><gtr:otherNames>Brittan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1476-9255</gtr:issn><gtr:outcomeId>54379ed4339348.39957450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>599F8DAE-E6BC-47A9-A168-EB0249BC053E</gtr:id><gtr:title>Swimming against the tide: drugs drive neutrophil reverse migration.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5aeb0c67fdf9cb4756bd82fe23617d8f"><gtr:id>5aeb0c67fdf9cb4756bd82fe23617d8f</gtr:id><gtr:otherNames>Lucas CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>543570bc68bfa9.89732403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77998894-36F3-4EBD-BEB4-9C77ECEAF946</gtr:id><gtr:title>Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28b1a25bedef401550366563cc3c49fc"><gtr:id>28b1a25bedef401550366563cc3c49fc</gtr:id><gtr:otherNames>Boyapati RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>56dff079b31ee4.59982785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D241089C-8B9B-4A8F-8301-FC04834E9345</gtr:id><gtr:title>Invertebrate extracellular phagocyte traps show that chromatin is an ancient defence weapon.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab9ebc3e1cf3b8a546aa3b876c2d1c1"><gtr:id>4ab9ebc3e1cf3b8a546aa3b876c2d1c1</gtr:id><gtr:otherNames>Robb CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>54357193eabd19.09103115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A8FBC0B-DC86-4BEB-ABA0-D73135684FDF</gtr:id><gtr:title>Oxygen levels determine the ability of glucocorticoids to influence neutrophil survival in inflammatory environments.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5190029ab216c357cc962e19a2158604"><gtr:id>5190029ab216c357cc962e19a2158604</gtr:id><gtr:otherNames>Marwick JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>pm_14466_26_23964116</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A05F0025-9B40-4D58-B30E-51581989FC34</gtr:id><gtr:title>The involvement of xanthohumol in the expression of annexin in human malignant glioblastoma cells.</gtr:title><gtr:parentPublicationTitle>The open biochemistry journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3822bd1cf4f54287ec635960025b6731"><gtr:id>3822bd1cf4f54287ec635960025b6731</gtr:id><gtr:otherNames>Festa M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1874-091X</gtr:issn><gtr:outcomeId>pm_15352_22_23407460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93739E12-F3D9-44B3-BD15-5B2B36D4755B</gtr:id><gtr:title>Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab9ebc3e1cf3b8a546aa3b876c2d1c1"><gtr:id>4ab9ebc3e1cf3b8a546aa3b876c2d1c1</gtr:id><gtr:otherNames>Robb CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5a748d2bc8a2a0.28382568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBBF7FDC-A6FC-4BB5-9032-EE7D5BDBBC47</gtr:id><gtr:title>Mechanism of neutrophil activation and toxicity elicited by engineered nanomaterials.</gtr:title><gtr:parentPublicationTitle>Toxicology in vitro : an international journal published in association with BIBRA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a403ab78896d1045ba1eb9207a87ae85"><gtr:id>a403ab78896d1045ba1eb9207a87ae85</gtr:id><gtr:otherNames>Johnston H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0887-2333</gtr:issn><gtr:outcomeId>56dff1905102d4.26198682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E9885FF-CC5F-4702-8AC6-CB4551AFFDF1</gtr:id><gtr:title>Wogonin induces eosinophil apoptosis and attenuates allergic airway inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5aeb0c67fdf9cb4756bd82fe23617d8f"><gtr:id>5aeb0c67fdf9cb4756bd82fe23617d8f</gtr:id><gtr:otherNames>Lucas CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>doi_55faa2aa251db8c4</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K013386/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>